Table 2 KEGG pathways of the genes downregulated or upregulated in U373MG cells following exposure to anti-cancer chemical compounds
ET-770 (the Compound 1a) | ET-770 Derivative (the Compound 3) | RM (the Compound 2a) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Downregulated Genes (n = 426) | Downregulated Genes (n = 417) | Downregulated Genes (n =274) | |||||||||
Rank | Pathway | P-Value | FDR | Rank | Pathway | P-Value | FDR | Rank | Pathway | P-Value | FDR |
1 | hsa04012:ErbB signaling pathway | 0.0006 | 0.71 | 1 | hsa04510:Focal adhesion | 0.0001 | 0.12 | 1 | hsa04070:Phosphatidylinositol signaling system | 0.0003 | 0.38 |
2 | hsa04360:Axon guidance | 0.0008 | 0.94 | 2 | hsa04360:Axon guidance | 0.0002 | 0.21 | 2 | hsa04916:Melanogenesis | 0.0019 | 2.17 |
3 | hsa04070:Phosphatidylinositol signaling system | 0.0041 | 4.69 | 3 | hsa04810:Regulation of actin cytoskeleton | 0.0007 | 0.80 | 3 | hsa05223:Non-small cell lung cancer | 0.0027 | 3.03 |
4 | hsa04520:Adherens junction | 0.0052 | 5.82 | 4 | hsa04020:Calcium signaling pathway | 0.0083 | 9.21 | 4 | hsa04510:Focal adhesion | 0.0032 | 3.51 |
5 | hsa05214:Glioma | 0.0076 | 8.42 | 5 | hsa04012:ErbB signaling pathway | 0.0093 | 10.22 | 5 | hsa04020:Calcium signaling pathway | 0.0043 | 4.69 |
6 | hsa04514:Cell adhesion molecules (CAMs) | 0.0097 | 10.63 | 6 | hsa04012:ErbB signaling pathway | 0.0046 | 5.10 | ||||
7 | hsa05214:Glioma | 0.0053 | 5.86 | ||||||||
8 | hsa04720:Long-term potentiation | 0.0074 | 8.01 | ||||||||
9 | hsa04912:GnRH signaling pathway | 0.0083 | 8.91 | ||||||||
10 | hsa04360:Axon guidance | 0.0084 | 9.08 | ||||||||
Upregulated Genes (n = 45) | Upregulated Genes (n = 84) | Upregulated Genes (n = 9) | |||||||||
Rank | Pathway | P-Value | FDR | Rank | Pathway | P-Value | FDR | Rank | Pathway | P-Value | |
1 | hsa04110:Cell cycle | 0.0053 | 4.58 | 1 | hsa04110:Cell cycle | 0.0077 | 6.84 | none | |||